An in-person dispensing requirement for a drug used in medication abortions is consistent with legal precedents and doesn’t pose a substantial obstacle to abortion access during the Covid-19 pandemic, the Food and Drug Administration told the U.S. Supreme Court Thursday.
The nation’s top court should lift a lower court order barring the agency from insisting that women go to doctor’s offices, clinics, or hospitals to pick up the drug mifepristone, also known as mifeprex, for the duration of the public health emergency caused by the novel coronavirus, FDA said.
FDA asked the court to stay an injunction issued by the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.